drugset

drugset / Trial / NCT00548418

Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

NCT00548418 ↗

Phase 2 Completed 27 enrolled Washington University School of Medicine Genentech, Inc. · collab GlaxoSmithKline · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer

Timeline

Start: 2007-02
Primary completion: 2012-12
Completion: 2012-12

Publications

Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul;130(1):64-8. doi: 10.1016/j.ygyno.2013.04.009. Epub 2013 Apr 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	—
Subject	Cisplatin	Other / unclassified	50 mg/m2	Intravenous
Subject	Topotecan	Small molecule	0.75 mg/m2	Intravenous

Indications